Friday, May 02, 2014
Johnson and Johnson Issues Alert For Fibroid Surgery Devices' Potentially Cancer Causing Process
Johnson and Johnson has stopped selling fibroid surgery devices Wednesday, due to potential cancer risks associated with their use.
The company told The Wall Street Journal more details were needed from medical professionals before sales resume.
"We believe that suspending the commercialization of these products until their role is better understood and redefined by the medical community is the appropriate course of action at this time," Johnson and Johnson said in the statement.
Johnson and Johnson told customers in an official statement that the decision did not come easy.
"This decision was not made lightly because we are well aware of the significant benefits that these products can offer many women," the company said."Since 1998, Ethicon's morcellation devices have enabled thousands of patients to have minimally invasive surgical hysterectomy and myomectomy procedures, instead of more invasive surgical procedures."
This process, known as morcellation, slashes body tissue for removal to help prevent cancer from spreading to other areas. But now, the United States Food and Drug Administration is concerned that exposed tissue could cause cancer to spread.